Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.
Chunkit Fung, Paul Dinh, Shirin Ardeshir-Rouhani-Fard...
https://pubmed.ncbi.nlm.nih.gov/29670654Actively Recruiting
Phase 2
Age: 18Years +
MALE
ID06932458
A Phase II Single-arm Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Led by Western University, Canada · Updated on 2025-07-20
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Testicular cancer is a rare adult cancer but the most common solid tumor in young men, with about 90% being germ cell tumors classified as seminoma or non-seminoma. Around 20% of seminoma patients have clinical stage II disease with limited retroperitoneal lymph node metastases. This trial explores an alternative to standard radiotherapy or chemotherapy treatments, which carry risks of serious short- and long-term side effects, by evaluating the role of surgery called Primary Retroperitoneal Lymph Node Dissection (RPLND).
CONDITIONS
Brief Title
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
- Adult males older than 18 years with pure seminoma on orchiectomy specimen
- Initial clinical stage I with retroperitoneal relapse or de novo clinical stage II at presentation
- Axial imaging of lymphadenopathy within 8 weeks of planned surgery
- No more than 2 enlarged retroperitoneal lymph nodes, each 3 cm or smaller
- Suitable for bilateral nerve-sparing retroperitoneal lymph node dissection
- Normal serum tumor markers (AFP, HCG, LDH) within 2 weeks before planned surgery
You will not qualify if you...
- Any condition considered too risky for retroperitoneal lymph node dissection by the surgeon
- Presence of non-seminoma component on orchiectomy specimen
- Serum alpha-fetoprotein (AFP) level above 20 at any time before or after orchiectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Hospital stay of up to 90 days
Participants undergo open bilateral nerve-sparing Retroperitoneal Lymph Node Dissection (RPLND) surgery and receive immediate post-operative care.
Approximately 1 hospital stay
Post-operative Follow-up
Duration - Up to 2 years
Participants are monitored after surgery for safety, recovery, and recurrence of cancer.
Follow-up visits over 24 months
Trial Site Locations
Total: 1 location
1
London Health Sciences Centre
London, Ontario, Canada
Actively Recruiting
Loading map...
Research Team
K
Kaydee Connors
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors.
Sophie D Fosså, Alv A Dahl, Lene Thorsen...
https://pubmed.ncbi.nlm.nih.gov/35380874Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.
Robert J Hamilton, Christina Canil, Noa Shani Shrem...
https://pubmed.ncbi.nlm.nih.gov/35623007